nach oben

Erschienen in:

21.11.2023 | Peritoneal Surface Malignancy

Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin

verfasst von: Elad Sarfaty, MD, Nazanin Khajoueinejad, MD, Allen T. Yu, MD, PhD, Spiros Hiotis, MD, PhD, Benjamin J. Golas, MD, Umut Sarpel, MD, MSc, Daniel M. Labow, MD, MS, Noah A. Cohen, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) improves survival compared with chemotherapy alone in patients with peritoneal carcinomatosis (PC) of colorectal (CRC) origin, however, long-term survival data are lacking. We report the actual survival of patients who underwent CRS/HIPEC for PC of CRC origin with a minimum potential 5-year follow-up period to identify factors that preclude long-term survival.

Methods

We performed a retrospective analysis of a prospective database, analyzing patients undergoing CRS/HIPEC for PC of CRC origin from 2007 to 2017. Patients with aborted CRS/HIPEC, postoperative follow-up <90 days, or non-CRC histology were excluded. Overall survival (OS) and disease-free survival (DFS) were measured from date of surgery. Surviving patients with <60 months of follow-up were censored at date of last follow-up.

Results

A total of 103 patients met inclusion criteria and were analyzed. CC score 0–1 was achieved in 89.3% of patients, and median peritoneal cancer index (PCI) was 9 (interquartile range [IQR] 5–17). Ninety-day mortality was 2.9%. The median follow-up of survivors was 88 months. Five-year OS was 36%, and median OS was 42.5 months. Factors independently associated with poor survival included high PCI (PCI = 14–20, hazard ratio [HR] 3.1, p = 0.007, and PCI > 20, HR 5.3, p ≤ 0.001) and incomplete CRS (CC score-2, HR 2.96, p = 0.02). Patients with low PCI (0–6) had 5-year OS 60.7%.

Conclusions

Actual 5-year OS was 36% and median OS was 42.5 months. Our study demonstrates that patients with PC from CRC origin with low PCI who undergo complete surgical resection can achieve favorable long-term survival.

Tseng J, Bryan DS, Poli E, et al. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncol. 2017;18(6):711–2. https://doi.org/10.1016/S1470-2045(17)30336-4.CrossRefPubMed

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2019) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Sugarbaker PH. Surgical management of peritoneal carcinomatosis: diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373(3):189–96. https://doi.org/10.1007/BF01274232.CrossRefPubMed

Sugarbaker PH, Landy D, Pascal R. Intraperitoneal chemotherapy for peritoneal carcinomatosis from colonic or appendiceal cystadenocarcinoma: rationale and results of treatment. Prog Clin Biol Res. 1990;354B:141–70.PubMed

Sugarbaker PH. Management of peritoneal carcinomatosis. Acta Med Austriaca. 1989;16(3–4):57–60.PubMed

Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. https://doi.org/10.1200/JCO.2003.04.187.CrossRefPubMed

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.CrossRefPubMed

Quénet F, Elias D, Roca L, et al. UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. https://doi.org/10.1016/S1470-2045(20)30599-4.CrossRefPubMed

Klaver CEL, Wisselink DD, Punt CJA, et al. COLOPEC collaborators group. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761–70. https://doi.org/10.1016/S2468-1253(19)30239-0.CrossRefPubMed

10.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), NCCN Guidelines Version 2.2022 Colon Cancer. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [12/09/2022]. To view the most recent and complete version of the guideline, go online to NCCN.org.

11.

Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41(3):678–700. https://doi.org/10.1200/JCO.22.01690.CrossRefPubMed

12.

Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-8. https://doi.org/10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010;28(10):1808.

13.

Beal EW, Ahmed A, Grotz T, et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219(3):478–83. https://doi.org/10.1016/j.amjsurg.2019.09.017.CrossRefPubMed

14.

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: PH Sugarbaker, editor. Peritoneal carcinomatosis: principles of management. Boston: Cancer treatment and research. Springer; 1996. https://doi.org/10.1007/978-1-4613-1247-5_23.CrossRef

15.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7. https://doi.org/10.1016/S0140-6736(07)61602-X.CrossRef

16.

Tabrizian P, Shrager B, Jibara G, Yang MJ, Romanoff A, Hiotis S, Sarpel U, Labow DM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg. 2014;18(5):1024–31. https://doi.org/10.1007/s11605-014-2477-5.CrossRefPubMed

17.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefPubMed

18.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.CrossRefPubMedPubMedCentral

19.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRefPubMed

20.

Harris PA, Taylor R, Minor BL, et al. REDCap Consortium. The REDCap consortium: building an international community of software partners. J Biomed Inform. 2019. https://doi.org/10.1016/j.jbi.2019.103208].CrossRefPubMedPubMedCentral

21.

Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900–7. https://doi.org/10.1097/SLA.0b013e3181a45d86.CrossRefPubMed

22.

Foster JM, Sleightholm R, Patel A, Shostrom V, Hall B, Neilsen B, Bartlett D, Smith L. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open. 2019;2(1):e186847. https://doi.org/10.1001/jamanetworkopen.2018.6847.CrossRefPubMedPubMedCentral

23.

Chicago Consensus Working Group. The Chicago consensus on peritoneal surface malignancies: management of colorectal metastases. Ann Surg Oncol. 2020;27(6):1761–7. https://doi.org/10.1245/s10434-020-08315-x.CrossRef

24.

Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ. Research committee of the European Society of Coloproctology. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017;19(3):224–36. https://doi.org/10.1111/codi.13593.CrossRefPubMed

25.

Rovers KP, Bakkers C, Simkens GAAM, et al. Dutch peritoneal oncology group (DPOG); Dutch colorectal cancer group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19(1):390. https://doi.org/10.1186/s12885-019-5545-0.CrossRefPubMedPubMedCentral

26.

Rovers KP, Bakkers C, Nienhuijs SW, et al. Dutch peritoneal oncology group and the dutch colorectal cancer group. Perioperative systemic therapy versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: A phase 2 randomized clinical trial. JAMA Surg. 2021;156(8):710–20. https://doi.org/10.1001/jamasurg.2021.1642.CrossRefPubMed

27.

Hanna DN, Ghani MO, Hermina A, et al. Diagnostic laparoscopy in patients with peritoneal carcinomatosis is safe and does not delay cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am Surg. 2022;88(4):698–703. https://doi.org/10.1177/00031348211048819.CrossRefPubMed

28.

de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Doukas M, Verhoef C, Burger JWA. The accuracy of the surgical peritoneal cancer index in patients with peritoneal metastases of colorectal cancer. Dig Surg. 2021;38(3):205–11. https://doi.org/10.1159/000513353.CrossRefPubMed

29.

Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958–64. https://doi.org/10.1245/s10434-015-4387-5.CrossRefPubMed

30.

Birgisson H, Enblad M, Artursson S, Ghanipour L, Cashin P, Graf W. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2020;46(12):2283–91. https://doi.org/10.1016/j.ejso.2020.07.039.CrossRefPubMed

31.

Bhagwandin SB, Fouad R, Labow DM. The surgical management of peritoneal carcinomatosis of colorectal origin. Oncology. 2016;30(11):1002-4–1006-7.PubMed

32.

Hassan S, Malcomson L, Soh YJ, Wilson MS, Clouston H, O’Dwyer ST, Kochhar R, Aziz O. Patterns and timing of recurrence following CRS and HIPEC in colorectal cancer peritoneal metastasis. Eur J Surg Oncol. 2023;49(1):202–8. https://doi.org/10.1016/j.ejso.2022.07.019.CrossRefPubMed

33.

Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: A meta-analysis. Ann Surg. 2016;263(6):1102–11. https://doi.org/10.1097/SLA.0000000000001593.CrossRefPubMed

34.

Leigh NL, Solomon D, Feingold D, et al. Improved survival with experience: a 10-year learning curve in hyperthermic intraperitoneal chemotherapy and cytoreductive surgery. Ann Surg Oncol. 2020;27(1):222–31. https://doi.org/10.1245/s10434-019-07518-1.CrossRefPubMed

Titel: Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin
verfasst von: Elad Sarfaty, MD
Nazanin Khajoueinejad, MD
Allen T. Yu, MD, PhD
Spiros Hiotis, MD, PhD
Benjamin J. Golas, MD
Umut Sarpel, MD, MSc
Daniel M. Labow, MD, MS
Noah A. Cohen, MD
Publikationsdatum: 21.11.2023
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 3/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14608-8

Neu im Fachgebiet Chirurgie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Timing to Surgery and Lymph Node Upstaging in Gastric Cancer: An NCDB Analysis

Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors

ASO Author Reflections: Decoding the Complexities of Cytoreductive Surgery and HIPEC Procedural Billing: A Potential Blueprint for the Peritoneal Surface Malignancy Surgeon

ASO Visual Abstract: The Effectiveness of Screening Total Colonoscopy for Preoperative Patients with Gastric Cancer

Biopsychosocial Late Effects After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal and Appendiceal Cancer: A National Prospective Cohort Study

Intra-Patient Heterogeneity in Micro-satellite-stable Colorectal Metastases: Does Immunotherapy Have a Role in Colorectal Peritoneal Metastases?

Update Chirurgie